Changshan Pharmaceutical shares fell 15.15% to 24.92 yuan at close on June 17. A China weight-loss drug index dropped 1.82%. The move followed a report that Changshan’s GLP-1 obesity candidate Aibennatide, having just completed a prior round of supplementary submissions, received a second-round supplementary-data notice from the CDE, cooling near-term上市 expectations. Changshan said it is not accepting media interviews. Several listed weight-loss companies said Aibennatide is Changshan’s independ

Changshan Pharmaceutical shares fell 15.15% to 24.92 yuan at close on June 17. A China weight-loss drug index dropped 1.82%. The move followed a report that Changshan’s GLP-1 obesity candidate Aibennatide, having just completed a prior round of supplementary submissions, received a second-round supplementary-data notice from the CDE, cooling near-term上市 expectations. Changshan said it is not accepting media interviews. Several listed weight-loss companies said Aibennatide is Changshan’s independently developed single-target GLP-1; competition is most intense among single-target products such as semaglutide and liraglutide, while many firms are developing dual- and triple-target GLP-1s. Firms added a delay to Aibennatide would primarily affect Changshan, not peer concept stocks; an unnamed executive said single-target generics are expected around 2027 and are unrelated to Changshan’s approval timeline.